Large Scale Mass Spectrometry Profiling: Accelerated Biomarker Discovery to Drive Drug Development

Dr. Mo Jain, Founder and CEO of Sapient, discusses a next-generation mass spectrometry-based platform that can assay more than 11,000 circulating factors per biosample in less than 1 minute per sample run. He also highlights a series of real world case studies in which these technologies have been applied to rapidly identify sensitive and specific biomarkers of biological processes, disease progression, and drug responsiveness to advance and accelerate drug development pipelines.